Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,437 | 128 | 91.1% |
| Education | $237.71 | 29 | 8.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $380.76 | 23 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $366.52 | 32 | $0 (2023) |
| PFIZER INC. | $301.32 | 18 | $0 (2023) |
| Novo Nordisk Inc | $266.71 | 14 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $223.95 | 15 | $0 (2023) |
| Lilly USA, LLC | $151.06 | 8 | $0 (2021) |
| GlaxoSmithKline, LLC. | $144.16 | 6 | $0 (2024) |
| Philips Electronics North America Corporation | $128.82 | 5 | $0 (2019) |
| Otsuka America Pharmaceutical, Inc. | $123.81 | 5 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $90.72 | 4 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23.76 | 1 | GlaxoSmithKline, LLC. ($23.76) |
| 2023 | $441.67 | 28 | E.R. Squibb & Sons, L.L.C. ($132.30) |
| 2022 | $222.92 | 16 | E.R. Squibb & Sons, L.L.C. ($125.90) |
| 2021 | $194.15 | 9 | Takeda Pharmaceuticals U.S.A., Inc. ($46.69) |
| 2020 | $402.42 | 23 | AstraZeneca Pharmaceuticals LP ($89.06) |
| 2019 | $475.42 | 24 | Boehringer Ingelheim Pharmaceuticals, Inc. ($117.76) |
| 2018 | $447.12 | 24 | Philips Electronics North America Corporation ($102.29) |
| 2017 | $467.05 | 32 | Boehringer Ingelheim Pharmaceuticals, Inc. ($112.38) |
All Payment Transactions
157 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/20/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: RESPIRATORY | ||||||
| 11/02/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: PSYCHIATRY | ||||||
| 09/29/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $17.37 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/15/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: Diabetes | ||||||
| 09/07/2023 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: PAIN | ||||||
| 08/25/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $33.05 | General |
| Category: RESPIRATORY | ||||||
| 08/18/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/18/2023 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $20.82 | General |
| Category: Neuroscience | ||||||
| 08/17/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: PSYCHIATRY | ||||||
| 07/28/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $22.58 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/14/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Education | In-kind items and services | $9.09 | General |
| Category: Cardiovascular | ||||||
| 07/14/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Education | In-kind items and services | $9.09 | General |
| Category: Cardiovascular | ||||||
| 06/28/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Education | In-kind items and services | $9.09 | General |
| Category: Cardiovascular | ||||||
| 05/31/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Education | In-kind items and services | $9.09 | General |
| Category: Cardiovascular | ||||||
| 05/31/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Education | In-kind items and services | $9.09 | General |
| Category: Cardiovascular | ||||||
| 05/05/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Education | In-kind items and services | $9.09 | General |
| Category: Cardiovascular | ||||||
| 04/20/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.13 | General |
| Category: Cardiovascular | ||||||
| 04/07/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Education | In-kind items and services | $9.09 | General |
| Category: Cardiovascular | ||||||
| 03/24/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: Diabetes | ||||||
| 03/21/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Education | In-kind items and services | $9.09 | General |
| Category: Cardiovascular | ||||||
| 03/16/2023 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $13.60 | General |
| Category: Diabetes | ||||||
| 03/09/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Education | In-kind items and services | $9.09 | General |
| Category: Cardiovascular | ||||||
| 03/09/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Education | In-kind items and services | $9.09 | General |
| Category: Cardiovascular | ||||||
| 02/09/2023 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $27.78 | General |
| Category: PSYCHIATRY | ||||||
| 02/09/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Education | In-kind items and services | $9.09 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 554 | 805 | $228,591 | $66,578 |
| 2022 | 8 | 439 | 669 | $200,759 | $57,934 |
| 2021 | 9 | 438 | 615 | $169,238 | $47,140 |
| 2020 | 9 | 418 | 650 | $139,255 | $33,321 |
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 160 | 363 | $121,431 | $29,590 | 24.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 120 | 120 | $40,928 | $15,850 | 38.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 51 | 82 | $38,305 | $10,954 | 28.6% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 44 | 44 | $4,752 | $3,173 | 66.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 60 | 60 | $3,256 | $1,884 | 57.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $7,775 | $1,681 | 21.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 32 | $7,534 | $1,418 | 18.8% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 12 | 16 | $2,174 | $687.04 | 31.6% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 18 | 18 | $756.00 | $602.82 | 79.7% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 16 | 16 | $943.50 | $501.59 | 53.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 13 | 15 | $568.20 | $165.62 | 29.1% |
| 81002 | Urinalysis, manual test | Office | 2023 | 16 | 21 | $168.00 | $71.61 | 42.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 146 | 333 | $111,395 | $26,464 | 23.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 110 | 110 | $37,518 | $14,759 | 39.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 48 | 77 | $35,969 | $9,841 | 27.4% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 44 | 45 | $4,860 | $3,091 | 63.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 28 | $6,593 | $1,707 | 25.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 49 | 51 | $3,159 | $1,528 | 48.4% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 14 | 14 | $848.86 | $428.35 | 50.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 11 | 11 | $416.68 | $116.54 | 28.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 121 | 263 | $85,796 | $19,129 | 22.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 82 | 82 | $27,542 | $11,227 | 40.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 51 | 68 | $31,264 | $8,322 | 26.6% |
| 90662 | Vaccine for influenza for injection into muscle, split virus, preservation free | Office | 2021 | 39 | 39 | $2,691 | $2,480 | 92.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 30 | 43 | $9,934 | $2,458 | 24.7% |
About Dr. Kai Li, MD
Dr. Kai Li, MD is a Internal Medicine healthcare provider based in Oregon City, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427153238.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kai Li, MD has received a total of $2,675 in payments from pharmaceutical and medical device companies, with $23.76 received in 2024. These payments were reported across 157 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($2,437).
As a Medicare-enrolled provider, Li has provided services to 1,849 Medicare beneficiaries, totaling 2,739 services with total Medicare billing of $204,974. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Oregon City, OR
- Active Since 09/14/2006
- Last Updated 05/18/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1427153238
Products in Payments
- ELIQUIS (Drug) $384.75
- JARDIANCE (Drug) $166.07
- TRULICITY (Drug) $138.58
- Ozempic (Drug) $136.15
- TRADJENTA (Drug) $117.76
- LYRICA (Drug) $111.59
- REXULTI (Drug) $107.90
- Victoza (Drug) $94.71
- SYMBICORT (Drug) $82.97
- CHANTIX (Drug) $79.31
- Wellcentive Undiv (Device) $77.29
- TRELEGY ELLIPTA (Drug) $70.03
- FARXIGA (Drug) $60.14
- TRINTELLIX (Drug) $46.69
- COMBIVENT RESPIMAT (Drug) $46.40
- Myrbetriq (Drug) $44.36
- Trintellix (Drug) $44.03
- LONHALA MAGNAIR (Drug) $42.22
- ANORO (Drug) $41.08
- SOLIQUA 100/33 (Biological) $39.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Oregon City
Shane Rogosin, Md, MD
Internal Medicine — Payments: $621.19
Ramandeep Sidhu, Md, MD
Internal Medicine — Payments: $474.13
Danielle Cataxinos, Do, DO
Internal Medicine — Payments: $118.80
Brandon Young, M.d, M.D
Internal Medicine — Payments: $107.91
Dr. Zibing Woodward, M.d, M.D
Internal Medicine — Payments: $92.90
Sonali Saluja, Md, MD
Internal Medicine — Payments: $34.96